Dry EyePhase 4NCT04515329
Tear Film Markers in Dry Eye Syndrome
A Phase 4 study testing Cyclosporine and Artificial tear in people with Dry Eye, run by Vishal Jhanji at 1 site in United States.
Trial summary
Dry eye is the most common reason for visit to an ophthalmologist's office. The prevalence is on the rise and is mainly attributed to factors such as increased environmental pollution and contact lens use. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Dry Eye
- What is being tested?
- Cyclosporine and Artificial tear
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 0 participants
- Where
- 1 siteUnited States
- Study dates
- 8 Dec 2023to 8 Dec 2023
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Diagnosed with Dry Eye, but who have not been prescribed a drug to treat this condition.
- 18 years of age and older
- OSDI score > 12
Who cannot join
- Younger than 18 years of age.
- Any other associated eye diseases other than Dry Eye.
- Inability to understand and give informed consent.
- Patients diagnosed with Dry Eye who are already using Cequa.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Tear Film Markers in Dry Eye Syndrome: Impact of Immunomodulatory Therapy
Dry eye is the most common reason for visit to an ophthalmologist's office. The prevalence is on the rise and is mainly attributed to factors such as increased environmental pollution and contact lens use. The current management options are limited to over the counter artificial tear drops and three FDA-approved drugs. Of these, cyclosporine has been used worldwide for treating mild to moderate dry eyes. The earlier version consisted of 0.05% cyclosporine which worked well for a limited number of inflammatory dry eye conditions. Recently, 0.09% cyclosporine was approved by the FDA. The nearly double concentration is expected to be more beneficial for severe inflammation which is often seen in Sjögren syndrome and other Rheumatological conditions associated with dry eyes. In this pilot project, the investigator proposes to evaluate the change in expression of SLURP1 and other markers of ocular surface inflammation before and after treatment with 0.09% cyclosporine eye drops.
Read the detailed description
Subjects will be recruited based on their diagnosis of dry eyes and an estimate of the severity of the disease that would be made by the investigator based on the patient's history and clinical examination.
Dry Eye Severity is determined by scoring > 12 on the Ocular Surface Disease Index (OSDI) rubric, which is standard practice.
Patients who have been diagnosed with dry eye, but who have not been prescribed a drug to treat that condition, will be recruited.
After signing a consent form, subjects will complete their routine care eye exam.
The PI will include consecutive patients for each arm. Once the mandate is completed in both arms, the investigator will stop the recruitment. The investigator will include patients who will choose to use artificial tear drops in one group. For the other group, the investigator will choose patients who would electively agree to use cyclosporine eyedrops. If these patients choose not to be a part of the study, they will still end up using the treatment that they would like to use.
- Study arm: Treatment will be commenced with cyclosporine eye drops twice daily with preservative-free artificial tear drops 4 times a day (Treatment).
- Control arm: Preservative-free artificial tear drops 4 times a day (Control).
Eye drop timetable:
- If instructed to take 4 times a day, the subject will instill one drop in the morning, the afternoon, the early evening, and before bedtime.
- If instructed to take 2 times a day, the subject will instill one drop in the morning and the evening.
- Subjects will also be instructed to space eye drops by 3-5 minutes.
Both the Cyclosporine and Artificial Tears will be ordered by the subject's doctor, which will be available through the subject's pharmacist. These drops are normally prescribed as part of the subject's routine care.
Both subjects and physicians will be aware of the type of treatment; however the data entry and analysis would be blinded. This will be done by giving each individual subject a linking code.
Subjects will self-administer the eyedrops for 8 weeks.
---------------------------------------------------------
Research Procedures:
The following samples would be collected at baseline and at Week 8:
Baseline (Visit 1):
- Randomization
- Tear Fluid Collection
- Impression Cytology
Week 4 (Visit 2):
- Data collection: Subject will follow up normally with their ophthalmologist as part of their routine care eye exam. The following will be collected: Demographics; Clinical History and office visits; Images and Photography; and Microbiology records.
Week 8 (Visit 3):
- Tear Fluid Collection
- Impression Cytology
Visits 1 and 3 will add up to 20 minutes to the participant's routine care eye exam.
---------------------------------------------------------
Explanation of Procedures:
Numbing Anesthesia Drop (Proparacaine 0.5%):
Subject will receive a numbing anesthesia drop (Proparacaine 0.5%) in the eye that is inflamed as part of their standard of care. The effect of this drop will wear off in 20 minutes after instillation, but the subject is not required to stay until the numbing subsides.
Tear Fluid Collection (Schirmer Testing):
A small amount of the subject's tears will be collected by placing paper strips in the corner of their eye.
Impression Cytology:
The investigators will collect a single sample of material from the surface of the subject's eye and then evaluate it on a cellular level. During impression cytology the subject will be asked to look straight ahead with their chin slightly lifted. A drop of anesthetic eye drops is instilled in the lower fornix of the eye. The plunger of the impression cytology device (EYEPRIM; OPIA Technologies SAS, Paris, France, or equivalent) is pushed to touch the cornea with the membrane gently for 5 seconds. The pressure is released before removing the device. The membrane is then carefully transferred from the device into a 1.5-mL tube using a pair of sterile forceps. Multiple EYEPRIM membranes may be collected. One drop of artificial tear drop would be instilled on the surface of the eye. The participant would be asked to close his/her eye for a few seconds. A capillary tube or Schirmer's strip would be used to collect the tear film.
The total duration of research procedures will be approximately 20 minutes.
---------------------------------------------------------
Samples:
Microbiology analysis will be processed at the UPMC Eye Center's Ophthalmology Microbiology Lab.
The tear fluid samples would be analyzed by ELISA for:
- Matrix metalloproteinase-9
- SLURP-1
- HLA-DR5
- IL-1RA,
- IL-6, and
- IL-8
Impression cytology samples would be used to isolate total RNA, which will be converted to cDNA and used for QPCR evaluation of corresponding transcripts for the above targets. QPCRs along with ELISAs would provide convincing evidence to elucidate the effect(s) of 0.09% cyclosporine on expression of these markers of ocular surface inflammation. At the end of the study, the subject assignments will be unmasked and the difference between the treatment and the control groups analyzed.
- Conditions
- Dry Eye
- Being tested
- Cyclosporine, Artificial tear
- Medical subject headings
- Dry Eye Syndromes
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CyclosporineDrug
Also called Cequa
Eye drops taken twice daily.
Artificial tearDrug
Also called Preservative-free artificial tears
Preservative-free artificial tear drops 4 times a day.
| Study group | Role | What they receive |
|---|---|---|
| Cyclosporine + Artificial Tears | Experimental | Cyclosporine eye drops twice daily (Treatment) with preservative-free artificial tear drops 4 times a day (Control). Receives: Drug: Cyclosporine; Drug: Artificial tear |
| Artificial Tears | Other | Preservative-free artificial tear drops 4 times a day (Control). Receives: Drug: Artificial tear |
What is being measured
The primary outcome is the main question the study is designed to answer.
Tear Film Cytokines
Change from Baseline in tear film cytokines at 6 months. The tear fluid samples would be analyzed by ELISA for: Matrix metalloproteinase-9; SLURP-1; HLA-DR5; IL-1RA; IL-6; and IL-8.
Measured: At the time of sample collection (Baseline and Month 6).
Secondary outcomes (1)
OSDI Score
Change is Ocular Surface Disease Index (OSDI) score at Month 6.
The OSDI quickly assesses the symptoms of ocular irritation in dry eye disease and how they affect functioning related to vision. This 12-item questionnaire assesses dry eye symptoms and the effects it has on vision-related function in the past week of the patient's life. The questionnaire has 3 subscales: ocular symptoms, vision-related function, and environmental triggers. Patients rate their responses on a 0 to 4 scale with 0 corresponding to "none of the time" and 4 corresponding to "all of the time." A final score is calculated which ranges from 0 to 100 with scores 0 to 12 representing normal, 13 to 22 representing mild dry eye disease, 23 to 32 representing moderate dry eye disease, and greater than 33 representing severe dry eye disease.
Measured: Last follow-up (Month 6).
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Aug 2020
- Study start8 Dec 2023
- Primary completion8 Dec 2023
- Study completion8 Dec 2023
Why it stopped: No participants were enrolled. Study never started.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Dry EyeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- * Study arm: Treatment will be commenced with cyclosporine eye drops twice daily with preservative-free artificial tear drops 4 times a day (Treatment). * Control arm: Preservative-free artificial tear drops 4 times a day (Control).
- Masking
- None (open label)
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- Vishal Jhanji
- Sponsor type
- University, hospital or other
- Collaborators
- Sun Pharmaceutical Industries Limited
- Responsible party
- Sponsor-investigator, Vishal Jhanji, University of Pittsburgh
- Investigators
- Vishal Jhanji, MD, Principal investigator, UPMC Eye Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04515329
- Sponsor's protocol ID
- STUDY20010206
- Status last verified
- Dec 2023
- First submitted
- 5 Aug 2020
- Last updated
- 18 Dec 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Dec 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Tear Film Markers in Dry Eye Syndrome: Impact of Immunomodulatory Therapy
- ClinicalTrials.gov ID
- NCT04515329
- Acronym / sponsor ID
- STUDY20010206
- Conditions
- Dry Eye
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- WithdrawnReason stopped: No participants were enrolled. Study never started.
- Enrolment
- 0 participants (actual)
- Lead sponsor
- Vishal JhanjiUniversity, hospital or other
- Collaborators
- Sun Pharmaceutical Industries Limited
- Study start
- 8 Dec 2023 (actual)
- Primary completion
- 8 Dec 2023 (actual)
- Study completion
- 8 Dec 2023 (actual)
- First posted
- 17 Aug 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Dry eye is the most common reason for visit to an ophthalmologist's office. The prevalence is on the rise and is mainly attributed to factors such as increased environmental pollution and contact lens use. The current management options are limited to over the counter artificial tear drops and three FDA-approved drugs. Of these, cyclosporine has been used worldwide for treating mild to moderate dry eyes. The earlier version consisted of 0.05% cyclosporine which worked well for a limited number of inflammatory dry eye conditions. Recently, 0.09% cyclosporine was approved by the FDA. The nearly double concentration is expected to be more beneficial for severe inflammation which is often seen in Sjögren syndrome and other Rheumatological conditions associated with dry eyes. In this pilot project, the investigator proposes to evaluate the change in expression of SLURP1 and other markers of ocular surface inflammation before and after treatment with 0.09% cyclosporine eye drops.
Detailed description
Subjects will be recruited based on their diagnosis of dry eyes and an estimate of the severity of the disease that would be made by the investigator based on the patient's history and clinical examination.
Dry Eye Severity is determined by scoring > 12 on the Ocular Surface Disease Index (OSDI) rubric, which is standard practice.
Patients who have been diagnosed with dry eye, but who have not been prescribed a drug to treat that condition, will be recruited.
After signing a consent form, subjects will complete their routine care eye exam.
The PI will include consecutive patients for each arm. Once the mandate is completed in both arms, the investigator will stop the recruitment. The investigator will include patients who will choose to use artificial tear drops in one group. For the other group, the investigator will choose patients who would electively agree to use cyclosporine eyedrops. If these patients choose not to be a part of the study, they will still end up using the treatment that they would like to use.
- Study arm: Treatment will be commenced with cyclosporine eye drops twice daily with preservative-free artificial tear drops 4 times a day (Treatment).
- Control arm: Preservative-free artificial tear drops 4 times a day (Control).
Eye drop timetable:
- If instructed to take 4 times a day, the subject will instill one drop in the morning, the afternoon, the early evening, and before bedtime.
- If instructed to take 2 times a day, the subject will instill one drop in the morning and the evening.
- Subjects will also be instructed to space eye drops by 3-5 minutes.
Both the Cyclosporine and Artificial Tears will be ordered by the subject's doctor, which will be available through the subject's pharmacist. These drops are normally prescribed as part of the subject's routine care.
Both subjects and physicians will be aware of the type of treatment; however the data entry and analysis would be blinded. This will be done by giving each individual subject a linking code.
Subjects will self-administer the eyedrops for 8 weeks.
---------------------------------------------------------
Research Procedures:
The following samples would be collected at baseline and at Week 8:
Baseline (Visit 1):
- Randomization
- Tear Fluid Collection
- Impression Cytology
Week 4 (Visit 2):
- Data collection: Subject will follow up normally with their ophthalmologist as part of their routine care eye exam. The following will be collected: Demographics; Clinical History and office visits; Images and Photography; and Microbiology records.
Week 8 (Visit 3):
- Tear Fluid Collection
- Impression Cytology
Visits 1 and 3 will add up to 20 minutes to the participant's routine care eye exam.
---------------------------------------------------------
Explanation of Procedures:
Numbing Anesthesia Drop (Proparacaine 0.5%):
Subject will receive a numbing anesthesia drop (Proparacaine 0.5%) in the eye that is inflamed as part of their standard of care. The effect of this drop will wear off in 20 minutes after instillation, but the subject is not required to stay until the numbing subsides.
Tear Fluid Collection (Schirmer Testing):
A small amount of the subject's tears will be collected by placing paper strips in the corner of their eye.
Impression Cytology:
The investigators will collect a single sample of material from the surface of the subject's eye and then evaluate it on a cellular level. During impression cytology the subject will be asked to look straight ahead with their chin slightly lifted. A drop of anesthetic eye drops is instilled in the lower fornix of the eye. The plunger of the impression cytology device (EYEPRIM; OPIA Technologies SAS, Paris, France, or equivalent) is pushed to touch the cornea with the membrane gently for 5 seconds. The pressure is released before removing the device. The membrane is then carefully transferred from the device into a 1.5-mL tube using a pair of sterile forceps. Multiple EYEPRIM membranes may be collected. One drop of artificial tear drop would be instilled on the surface of the eye. The participant would be asked to close his/her eye for a few seconds. A capillary tube or Schirmer's strip would be used to collect the tear film.
The total duration of research procedures will be approximately 20 minutes.
---------------------------------------------------------
Samples:
Microbiology analysis will be processed at the UPMC Eye Center's Ophthalmology Microbiology Lab.
The tear fluid samples would be analyzed by ELISA for:
- Matrix metalloproteinase-9
- SLURP-1
- HLA-DR5
- IL-1RA,
- IL-6, and
- IL-8
Impression cytology samples would be used to isolate total RNA, which will be converted to cDNA and used for QPCR evaluation of corresponding transcripts for the above targets. QPCRs along with ELISAs would provide convincing evidence to elucidate the effect(s) of 0.09% cyclosporine on expression of these markers of ocular surface inflammation. At the end of the study, the subject assignments will be unmasked and the difference between the treatment and the control groups analyzed.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- * Study arm: Treatment will be commenced with cyclosporine eye drops twice daily with preservative-free artificial tear drops 4 times a day (Treatment). * Control arm: Preservative-free artificial tear drops 4 times a day (Control).
| Arm | Type | Receives |
|---|---|---|
| Cyclosporine + Artificial Tears | Experimental | Drug: Cyclosporine, Drug: Artificial tearCyclosporine eye drops twice daily (Treatment) with preservative-free artificial tear drops 4 times a day (Control). |
| Artificial Tears | Other | Drug: Artificial tearPreservative-free artificial tear drops 4 times a day (Control). |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Diagnosed with Dry Eye, but who have not been prescribed a drug to treat this condition.
- 18 years of age and older
- OSDI score > 12
Key exclusion criteria (4 listed)
- Younger than 18 years of age.
- Any other associated eye diseases other than Dry Eye.
- Inability to understand and give informed consent.
- Patients diagnosed with Dry Eye who are already using Cequa.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CyclosporineAlso: CequaEye drops taken twice daily. | Drug | Cyclosporine + Artificial Tears |
| Artificial tearAlso: Preservative-free artificial tearsPreservative-free artificial tear drops 4 times a day. | Drug | Artificial Tears, Cyclosporine + Artificial Tears |
Primary outcome
Tear Film Cytokines
Time frame: At the time of sample collection (Baseline and Month 6).
Change from Baseline in tear film cytokines at 6 months. The tear fluid samples would be analyzed by ELISA for: Matrix metalloproteinase-9; SLURP-1; HLA-DR5; IL-1RA; IL-6; and IL-8.
1 secondary outcome
OSDI Score
Time frame: Last follow-up (Month 6).
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Dec 2023.
- Individual participant dataSharing planned: No
Related trials for Dry Eye
Not yet recruitingPhase 1
R-2487 in Patients With Sjogren's Syndrome (SjD)
Sjogren's Syndrome, Sjögren
RecruitingPhase 1
A Trial in Healthy Adult Participants and Adults With Autoimmune Diseases to Test How HBM7020 is Tolerated and How it Behaves in the Body
Rheumatoid Arthritis, Systemic Lupus Erythematosus
RecruitingObservational study
Pain Phenotyping of Rheumatic Diseases - An Observational Study
Rheumatic Diseases, Lupus Erythematosus, Systemic
RecruitingPhase 1/2
Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration
Dry Age-Related Macular Degeneration, Geographic Atrophy
RecruitingObservational study
The Pathogenesis and Natural History of Sjogren's Disease
Sjogren's Syndrome, Salivary Gland
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Vishal Jhanji, MD principal investigator
UPMC Eye Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Cyclosporine and Artificial tear in people with Dry Eye, run by Vishal Jhanji at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 18 Dec 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Tear Film Cytokines (time frame: At the time of sample collection (Baseline and Month 6).). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Dec 2023.